Non-Metastatic Castration Resistant Prostate Cancer (nmCRPC) Treatment Market Players:
- Pfizer Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Astellas Pharma Inc.
- Clovis Oncology, Inc.
- Johnson & Johnson Health Care Systems Inc.
- Bayer AG
- Orion Corporation
- Merck & Co., Inc.
- Novartis AG
- AstraZeneca PLC
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2026, the industry size of non-metastatic castration resistant prostate cancer treatment is estimated at USD 8.64 billion.
The global non-metastatic castration resistant prostate cancer treatment market size was over USD 8.28 billion in 2025 and is anticipated to witness a CAGR of around 4.8%, crossing USD 13.23 billion revenue by 2035.
North America is anticipated to command a 30% share of the market, owing to increasing awareness about nmCRPC and the need for innovative cancer treatment solutions.
Key players in the market include Pfizer Inc., Astellas Pharma Inc., Clovis Oncology, Inc., Johnson & Johnson Health Care Systems Inc., Bayer AG, Orion Corporation, Merck & Co., Inc., Novartis AG, AstraZeneca PLC.
